The anticipated 40–50% price drop in GLP-1 receptor agonists, driven by the entry of generics, is expected to significantly reshape India’s healthcare landscape.
“This growing demand is a direct reflection
of India’s escalating metabolic health crisis,” says Dr Vimal Pahuja, MD, Associate Director, Internal Medicine & Metabolic Physician, Diabetes & Weight Management Clinic, Dr. LH Hiranandani Hospital, Powai, Mumbai.
India is currently grappling with an epidemic of obesity and type 2 diabetes, largely fuelled by rapid urbanisation and increasingly sedentary lifestyles. Adding to this challenge is the “thin-fat” Indian phenotype, where individuals develop metabolic complications at relatively lower body mass indices.
“For many of these patients, GLP-1 therapies are not cosmetic luxuries, they are critical, life-altering interventions,” explains Dr. Pahuja.
However, despite the expected price correction, a sharp rise in legitimate prescriptions may not follow immediately.
“A major bottleneck lies within the medical community itself,” notes Dr Pahuja. “There is still limited awareness and a lack of specialised skills among many physicians when it comes to titration, dietary integration, and long-term management of these therapies.”
He adds that professional hesitation also stems from concerns around long-term safety.
“There remains a degree of skepticism regarding the long-term side-effect profile of these drugs,” he says.
Beyond the clinical setting, patient perception is being shaped and often distorted by social media.
“On one hand, these drugs are being glorified for rapid weight loss. On the other, misinformation and isolated horror stories are being amplified without proper medical context,” says Dr Pahuja. “This creates unnecessary fear and deters patients who genuinely need treatment.”
So, will more affordable generics transform obesity care in India?
“Yes, lowering costs can democratise access for a much larger segment of the population,” acknowledges Dr Pahuja. “But this is also a double-edged sword.”
He warns that increased accessibility without proper medical supervision could lead to misuse.
“If these drugs are used off-label or without guidance, patients risk serious complications, including sarcopenia (loss of muscle mass), malnutrition, and even pancreatitis,” he explains.
Ultimately, while affordability marks a significant step forward, experts stress that access alone is not enough.
“Making GLP-1 medications more affordable is a major breakthrough,” says Dr Pahuja. “But we must clearly distinguish between medical necessity and cosmetic use, actively combat misinformation, and urgently upskill healthcare providers to ensure these therapies are used safely and effectively.”
